Welcome back to another episode of The BioHub, we were delighted to welcome on Nick Manusos, the CEO of Kenai Therapeutics, a pioneering biotech company developing neuron replacement therapies for neurological disorders. Nick’s journey spans decades of innovation and leadership—from senior roles at global pharma giants like Baxter, Takeda, and Abbott, to founding and leading cutting-edge startups like Iota Biosciences and Opsis Therapeutics. Under his guidance, Kenai Therapeutics has secured groundbreaking funding and is advancing life-changing therapies for patients with Parkinson’s disease. He holds an MBA from Northwestern University’s Kellogg School of Management and a BBA from the University of Wisconsin, bringing a rare combination of business acumen and scientific vision to the table. Nick joins us today to share his insights on pioneering stem cell therapies, building biotech startups from the ground up, and what it takes to turn cutting-edge science into real-world solutions.

Guest Editor of our ‘Next steps in the gene editing revolution’ edition, Sven Kili (Partner, Saisei Ventures), takes us on a guided tour of the gene editing landscape, highlighting recent milestones, ...

A well-placed biotech investor says U.S. policies are straining life sciences startups — and more disruption is coming.

atient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on ne...

Someone at the FDA has placed Nicole Verdun, the Super Director of The Office of Therapeutic Products at the agency, and her deputy, Rachael Anatol, on administrative leave as of yesterday. The agency...

FDA lawyer and other federal health agency workers remain on paid leave amid Trump administration cuts, awaiting court decisions while searching for new jobs.

In a post-hoc analysis, Zambon et al. find that arsa-cel gene therapy improves nerve function in children with pre-symptomatic late-infantile metachromatic

Deerfield Management is back with its third healthcare venture fund, this time securing more than $600 million to create new drug development outfits, medical technology startups and adjacent computat...

Initial clinical data from Genocury and EsoBiotec shows promise for in vivo CAR-T therapy, with complete remission in lymphoma and myeloma patients without lymphodepletion.

HHS Secretary Robert F. Kennedy Jr. said Friday that 35 states had signed up to participate in a new payment model meant to improve access to and lower costs for gene therapies for sickle cell disease...

Saisei Ventures, a leading venture investment firm focused on advancing Japanese biotechnology and therapeutic innovations, today announced the launch of its...

Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple effect is already being felt across biopharma.

Biobanks help centralize specimen collections, store and disseminate data, and facilitate large-scale analyses. This Review discusses how biobanks facilitate genetics research towards advancing precis...

Researchers say woman treated for neuroblastoma as a child is longest known survivor after having CAR T-cell therapy

The president’s full-court press to dominate media and control cultural institutions is straight out of the authoritarian playbook

Professor discusses the week's regenerative medicine news including research on the idea of stem cell exhaustion and aging.